- Home
- CRDL vs BZUN Comparison
CRDL vs BZUN Comparison
Compare CRDL & BZUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- BZUN
- Stock Information
- Founded
- CRDL 2017
- BZUN 2007
- Country
- CRDL Canada
- BZUN China
- Employees
- CRDL N/A
- BZUN N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- BZUN Catalog/Specialty Distribution
- Sector
- CRDL Health Care
- BZUN Consumer Discretionary
- Exchange
- CRDL Nasdaq
- BZUN Nasdaq
- Market Cap
- CRDL 126.5M
- BZUN 144.4M
- IPO Year
- CRDL N/A
- BZUN N/A
- Fundamental
- Price
- CRDL $1.31
- BZUN $2.77
- Analyst Decision
- CRDL Strong Buy
- BZUN Buy
- Analyst Count
- CRDL 2
- BZUN 2
- Target Price
- CRDL $9.00
- BZUN $3.20
- AVG Volume (30 Days)
- CRDL 1.2M
- BZUN 229.7K
- Earning Date
- CRDL 08-26-2025
- BZUN 08-28-2025
- Dividend Yield
- CRDL N/A
- BZUN N/A
- EPS Growth
- CRDL N/A
- BZUN N/A
- EPS
- CRDL N/A
- BZUN N/A
- Revenue
- CRDL N/A
- BZUN $1,310,110,798.00
- Revenue This Year
- CRDL N/A
- BZUN $5.27
- Revenue Next Year
- CRDL N/A
- BZUN $3.46
- P/E Ratio
- CRDL N/A
- BZUN N/A
- Revenue Growth
- CRDL N/A
- BZUN 6.77
- 52 Week Low
- CRDL $0.77
- BZUN $2.12
- 52 Week High
- CRDL $2.63
- BZUN $4.38
- Technical
- Relative Strength Index (RSI)
- CRDL 51.92
- BZUN 51.59
- Support Level
- CRDL $0.94
- BZUN $2.73
- Resistance Level
- CRDL $1.55
- BZUN $2.77
- Average True Range (ATR)
- CRDL 0.13
- BZUN 0.11
- MACD
- CRDL -0.00
- BZUN 0.00
- Stochastic Oscillator
- CRDL 59.74
- BZUN 41.30
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About BZUN Baozun Inc.
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.